431 results about "Immunologic disorders" patented technology

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

The present disclosure provides a fusion protein comprising a TACI polypeptide and a use thereof, particularly a use for preventing or treating autoimmune diseases.

The invention provides an antibody-drug conjugate with a structure as shown in a formula (I) or a formula (I ') or a stereoisomer, a pharmaceutically acceptable salt or a solvate thereof, and also provides a preparation method and application thereof. The invention further provides a drug-linker derivative or a stereoisomer, a pharmaceutically acceptable salt or a solvate thereof. The antibody-drug conjugate provided by the invention has the advantages of being high in DAR value, good in uniformity, excellent in biological activity, good in targeting property, easy to prepare and the like, so that the antibody-drug conjugate has a good application prospect in treatment of immune diseases;

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The disclosure relates to a series of substituted imidazolecarboxamide compounds of formula I as BTK (Bruton's Tyrosine Kinase) inhibitors, and the methods of using the same for the treatment of autoimmune disease, inflammatory disease, cancer and potentially allergies.

The disclosure includes compounds of Formula (I) (1) wherein Q0, Q1, Q2, Q3, Q4, Z, W, i, j, m, n, Warhead, R0, R1, R3, R4, R5, R6, and R7, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

The application discloses a kind of recombinant polypeptide and its application in preparation of the drug for treating autoimmune disease.The polypeptide includes the following amino acid sequence: X1X2EX3RHRFRQLDX4;Wherein, X1 is S or A, X2 is E or Q, X3 is M or I, X4 is S or T;The length of the polypeptide is 13-18 amino acids.The polypeptide provided by the application has stronger immunogenicity, is the important antigen peptide of chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS, type III prostatitis) and can be induced immune tolerance using the polypeptide, to provide effective treatment scheme for treating autoimmune disease (for example, type III prostatitis).The application also provides a kind of method for constructing mouse EAP model, using only one kind of adjuvant CFA, i.e.can successfully construct the model most matched with human chronic prostatitis / chronic pelvic pain syndrome.

The invention relates to the technical field of biological medicines, and discloses a blocking antibody targeting CXCL6 and an application of the blocking antibody in preparation of antitumor drugs. The antibody or antigen-binding fragment thereof is capable of binding specifically to human CXCL6 protein with high affinity (e.g., Kd < = 1 nM). According to the invention, the specificity and high affinity of the antibody are verified by Western Blot, immunofluorescence, immunohistochemistry and surface plasmon resonance (SPR) technologies. Functional experiments show that the antibody can effectively block CXCL6-induced neutrophil chemotaxis, including in Transwell, a three-dimensional gel model and a zebra fish living body model. Besides, in a mouse MC38 colon cancer model, the antibody shows remarkable anti-tumor activity and can inhibit tumor growth driven by CXCL6. The invention also provides a pharmaceutical composition containing the antibody, and application of the antibody in preparation of drugs for preventing or treating diseases (such as inflammatory diseases, autoimmune diseases and cancers) related to abnormal expression or activity of CXCL6.

The application discloses an epoxy compound and application thereof, and particularly discloses an epoxy compound as shown in formula I, a pharmaceutically acceptable salt or a stereoisomer thereof and application thereof. The compound has high inhibitory activity on beta5i and beta1i, and has low inhibitory level on beta5c and beta1c, the compound has high selectivity, and can be used for treating autoimmune diseases.

The present invention relates to formula (I): [Formula 1] A compound of TIFF2026514449000425.tif27170, or its tautomers, stereoisomers, salts, solvates, or N-oxides, wherein A 1 ~A 6 X, Y, R 7a , R 7b , R 8a , and R 8b The claims are as defined. The present invention further relates to pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, and their uses as agents, in particular as agents having METTL3 inhibitory activity, and advantageously for use in the treatment or prevention of cancer, or autoimmune diseases, neurological diseases, infectious diseases, or inflammatory diseases.

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

The present invention relates to compositions and methods for subpopulation-specific modulation of cell function and for treating repeat expansion disorders comprising genetic, degenerative, neurological and cellular diseases, including immune disorders. Also provided are research kits for subpopulation-specific modulation of protein activity and the corresponding potential to discover novel therapeutic compositions. More specifically, the disclosed compositions and methods selectively up- or downregulate at least a first population of a cellular protein or therapeutic target with minimal or negligible effect on the activity of at least a second population of the cellular protein or therapeutic target.

As disclosed herein a precision based immunomolecular augmentation (PBIMA) high specificity patient profiling networked computer system, rapid therapeutic vaccine design method, and personalized vaccine, which utilizes immuno-molecular biopathway HLA affinity mapping and selection prediction ranking tools. This PBIMA approach comprises: Strategic-Selection, Molecular-Mapping, Antigen-Alignment, Receptor-Recognition, and Tactical Technology (SMART). The platform obtains data from a patient's genes and proteins as input. NGS data, including WES, WGS, ctDNA and cfDNA, RNAseq uses as input. PBIMA comprises a gene-protein-cell Cloud-based sequence editing interface to select the high confidence peptides. The PBIMA vaccine is a solution-based multi-purpose vaccine design strategy. PBIMA technology can produce therapeutic vaccines for cancer, autoimmune, neurodegenerative, inflammation-driven disease, and novel pathogen infection treatment. PBIMA therapeutic design is multi-mechanistic and broad-spectrum.

The present invention relates to certain compounds that function as inhibitors of DHX9 activity (RNA Helicase A / RHA or Nuclear DNA Helicase II / NDH II). The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions 5 comprising them, and to their use in the treatment of proliferative disorders, such as cancer, autoimmune and infectious diseases, as well as other diseases or conditions in which DHX9 activity is implicated.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazo-pyridine structure, or compounds having a pyridinyl-purine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and are useful as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes (e.g., any type or form of diabetes, including type-1 or type-2), autoimmune diseases, inflammatory disorders (e.g., airway inflammation), cancer (e.g., glioblastoma, prostate cancer), diabetes, and other diseases.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

Disclosed herein are branched chain amino acid transaminase 1 (BCAT1) inhibitors and uses thereof. More specifically, disclosed are BCAT1 inhibitors that limit amino acid metabolism essential for CD4+ T-cell responses and their use in preventing, improving, or treating inflammatory disease or autoimmune disease. By identifying that BCAT1 acts as a major regulator in the inflammatory response of CD4+ T-cells, it is possible to regulate the inflammatory response by CD4+ T cells secreting interleukin-17 (IL-17), which is a major immune cell of autoimmune diseases, by utilizing a BCAT1 inhibitor.

This invention relates to a pharmaceutical composition for treating autoimmune diseases. The pharmaceutical composition for treating autoimmune diseases comprises an antibody and an inhibitor, wherein the antibody includes at least one of an OX40 antibody and an OX40L antibody, and the inhibitor includes at least one of a Janus kinase inhibitor and a RORγt inhibitor. In the above-mentioned pharmaceutical composition for treating autoimmune diseases, the Janus kinase inhibitor and / or the RORγt inhibitor can inhibit the secretion of IL17A by Treg cells induced by OX40 antibody and / or OX40L antibody, thereby reducing IL17A-promoted pathological inflammation and improving the efficacy of OX40 antibody and / or OX40L antibody in treating autoimmune diseases.

The present disclosure relates to methods of treating an autoimmune disease or disorder by administering an antibody that specifically binds to human CD94, as well as related uses, kits, and articles of manufacture. In some embodiments, the methods comprise administering the anti-CD94 antibody to an individual in need thereof at one or more doses of 24mg, 80mg, 240mg, or 450mg.

Compound of formula (I) able to simultaneously modulate Store Operated Calcium Entry (SOCE) and human dihydroorotate dehydrogenase (hDHODH). The disclosure also relates to compositions and uses of compounds of formula (I) for treatment of autoimmune, inflammatory, and chronic degenerative diseases, as well as neurodegenerative and multisystem inflammatory diseases associated with SOCE overactivation and DHODH pathway alterations, while avoiding immunosuppression, the main side effect of the currently available therapies.

To provide Akt3 modulators and compounds and pharmaceutical compositions for treating diseases by modulation of Akt3 signaling.SOLUTION: A compound of Formula Ib or Ic, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound for treating a disease in a subject in need thereof, A pharmaceutical composition wherein the treatment comprises administering to a subject an effective amount of the compound; optionally wherein the disease is selected from the group consisting of neurodegenerative diseases, cachexia, eating disorders, obesity, complications of obesity, inflammatory diseases, virally-induced inflammatory reactions, Gulf War Syndrome, tuberous sclerosis, retinitis pigmentosa, graft rejection, cancer, autoimmune diseases, ischemic tissue injury, traumatic tissue injury and combinations thereof.SELECTED DRAWING: Figure 6

The invention discloses an application of a grifola frondosa extract in preparation of a medicine for inhibiting myeloid-derived suppressor cells. The polysaccharide extract is a grifola frondosa sporocarp polysaccharide extract, and the molecular weight range of the polysaccharide extract is 0.5 * 10 < 4 >-149 * 10 < 4 > Da. The grifola frondosa extract inhibits the spleen of a tumorigenic mouse from generating MDSCs, inhibits the proportion and quantity of MDSCs in the blood and tumor tissue of the tumorigenic mouse, and improves the content and activity of CD3 + T and CD8 + T lymphocytes, so that the immune response ability of the body is improved, and the grifola frondosa extract is not only suitable for preparing anti-tumor drugs, but also suitable for treating inflammatory-mediated tissue damage, infectious diseases and other diseases. And preparing medicines for treating MDSCs related diseases such as autoimmune diseases and the like.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I):The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer.

Compositions related to synthetic PD-L1 peptides, chimeric PD-L1 peptides, and anti-PD-L1 antibodies, and methods for treating cancer, autoimmune diseases and Alzheimer's disease using said peptides or antibodies are disclosed.

The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which is important in inflammation. The present invention also relate to the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present invention also relates to the use of such short peptides to prevent or reverse autoimmune disease, and particular, diabetes, in individuals suffering from such disease. It also relates to methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells.

Provided are a quinolone analogue represented by formula (I), or a pharmaceutically acceptable salt, a stereoisomer, a racemate, a deuterated compound, or a solvent compound and a pharmaceutical composition thereof, and uses thereof in the preparation of drugs for treating tumors, autoimmune diseases, or diseases caused by bacteria, fungi or viruses.

The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.

The invention provides a regulatory T cell with improved phenotype and functional stability and a preparation method and application thereof. The regulatory T cell disclosed by the invention is co-expressed by membrane protein GARP and TGF-beta, and specifically, the TGF-beta comprises a C33S point mutation precursor TGF-beta 1; further, the regulatory T cell co-expresses a cytokine and a sorting marker, specifically, the cytokine comprises IL-10, and the sorting marker comprises a truncated nerve growth factor receptor tNGFR. The regulatory T cell has more stable phenotype and function stability in in-vivo and in-vitro environments, has important enlightenment value for improving the function stability problem of the regulatory T cell in an inflammatory environment, and has wide application prospects in the fields of treatment of autoimmune diseases, intervention of organ transplantation rejection and the like.